

Capstone Healthcare • 8601 Dunwoody Place, Suite 444 Atlanta GA 30350 • Phone: (678) 515-4524 • Fax: (470) 355-5462
 • Web: <http://www.capstonehealthcare.com> • CLIA #: 11D2073885 • Laboratory Director: John Hanson, PhD

Patient: Smith, Jane
 Date of Birth: Jan 01,1971
 Sex: Female

Physician: Dr. Robbins, Noah
 NPI #:UNKNOWN
 Practice: First Medical
 Phone: 678.123.4598

Date Collected: Mar 17, 2019
 Date Received: Mar 18, 2019
 Date Processed: Mar 18, 2019
 Specimen type/Source: Urine
 Sample ID: 1903181001

1. About This Report

This UTI Assay is a urinary tract infection screen that consists of clinical, molecular tests for microorganisms implicated in UTIs.

2. Molecular Diagnostic Results

-	<i>A. baumannii</i>	Negative	-	<i>K. pneumoniae</i>	Negative
-	<i>C. albicans</i>	Negative	-	<i>M. morgani</i>	Negative
-	<i>C. freundii</i>	Negative	-	<i>N. gonorrhoeae</i>	Negative
-	<i>C. glabrata</i>	Negative	-	<i>P. aeruginosa</i>	Negative
-	<i>C. trachomatis</i>	Negative	-	<i>P. mirabilis</i>	Negative
-	<i>E. aerogenes</i>	Negative	-	<i>P. stuartii</i>	Negative
-	<i>E. cloacae</i>	Negative	-	<i>P. vulgaris</i>	Negative
-	<i>E. coli</i>	Negative	-	<i>S. agalactiae</i>	Negative
M	<i>E. faecalis</i>	Positive	L	<i>S. aureus</i>	Positive
-	<i>E. faecium</i>	Negative	-	<i>S. saprophyticus</i>	Negative
-	<i>K. oxytoca</i>	Negative			

3. Antibiotic Treatment Options

The following table shows common treatment options for organisms assayed as present in this sample, combined with any positive or negative assayed resistance markers. "T" indicates a treatment option; "T:R" indicates a treatment option that may be affected by the detected resistance marker(s).

CFU equivalents

Low (L): $\leq 10^4$ | Medium (M): 10^4 to 10^6 | High (H): $\geq 10^6$ CFU

1903181001 - TEST, UTI - Reported Apr 02, 2019


The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2019, Coriell Life Sciences Inc.

Abundance	<i>E. faecalis</i>		Resistances
	M	L	
† ceftriaxone (Cephalosporins)	T:R	-	mecA
† ampicillin (Extended-Spectrum-Beta lactam)	T:R	T:R	mecA
† amoxicillin (Extended-Spectrum-Beta lactam)	T:R	-	mecA
gentamicin (Glycoside)	T	-	Not assayed
streptomycin (Glycoside)	T	T	Not assayed
† penicillin g (Narrow-Spectrum-Beta lactam)	-	T:R	mecA
nitrofurantoin (Nitrofurans)	T	T	Not assayed
linezolid (Oxazolidinone)	T	-	Not assayed
daptomycin (Peptide)	T	-	Not assayed
† tigecycline (Tetracyclines)	T:R	T:R	tetM
vancomycin (Vancomycin)	T	T	Negative

† Consider alternate treatment due to detected resistance marker(s).

Antibiotic Resistance

Assayed Resistance Markers



1903181001 - TEST, UTI - Reported Apr 02, 2019

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2019, Coriell Life Sciences Inc.

4. Microorganisms Tested by Capstone Healthcare

Organism/Assay	ctMean	Presence
<i>A. baumannii</i>	N/A	Not Detected
<i>ampC</i>	N/A	Not Detected
<i>blaOXA-48</i>	N/A	Not Detected
<i>C. albicans</i>	N/A	Not Detected
<i>C. freundii</i>	N/A	Not Detected
<i>C. glabrata</i>	N/A	Not Detected
<i>C. trachomatis</i>	N/A	Not Detected
<i>E. aerogenes</i>	N/A	Not Detected
<i>E. cloacae</i>	N/A	Not Detected
<i>E. coli</i>	N/A	Not Detected
<i>E. faecalis</i>	23.958	Detected
<i>E. faecium</i>	N/A	Not Detected
<i>ErmA</i>	N/A	Not Detected
<i>ErmB</i>	17.619	Detected
(Macrolide resistance)		
<i>ermC</i>	26.936	Detected
(Erythromycin resistance)		
<i>K. oxytoca</i>	N/A	Not Detected
<i>K. pneumoniae</i>	N/A	Not Detected
KPC	N/A	Not Detected
<i>M. organii</i>	N/A	Not Detected
<i>mecA</i>	25.978	Detected
(Methicillin resistance)		
<i>N. gonorrhoeae</i>	N/A	Not Detected
<i>P. aeruginosa</i>	N/A	Not Detected
<i>P. mirabilis</i>	N/A	Not Detected
<i>P. stuartii</i>	N/A	Not Detected
<i>P. vulgaris</i>	N/A	Not Detected
<i>QnrA</i>	N/A	Not Detected
<i>QnrB</i>	N/A	Not Detected
<i>S. agalactiae</i>	N/A	Not Detected
<i>S. aureus</i>	28.523	Detected
<i>S. saprophyticus</i>	N/A	Not Detected
<i>tetM</i>	17.49	Detected
(tetracycline-resistant ribosomal protection protein)		
<i>vanA1</i>	N/A	Not Detected
<i>vanA2</i>	N/A	Not Detected
<i>vanB</i>	N/A	Not Detected
<i>vanC1</i>	N/A	Not Detected

Limitation: An absence of detection does not imply the absence of microorganisms other than those listed or does not exclude the possibility that the target sequence is present below the limit of detection. The Capstone Molecular Diagnostic Report does not take into consideration patient history, drug-drug interactions, drug sensitivity, and/or allergies. It is the responsibility of the physician to determine appropriate drug and dosing choices based on all available data.

1903181001 - TEST, UTI - Reported Apr 02, 2019

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2019, Coriell Life Sciences Inc.

Capstone Molecular Diagnostic Report

Methodology: Array based assays simultaneously detect a wide array of bacteria, viruses, and parasites at analytical sensitivity and specificity >99%.

Disclaimer: These tests were developed and characterized by Capstone Healthcare and interpreted by Coriell Life Sciences, 4747 South Broad Street, Building 101, Suite 222, Philadelphia, PA 19112. The tests in this UTI panel have not been approved by the Food and Drug Administration. The FDA has determined that such approval is not necessary, provided that the laboratory both (1) maintains its good standing as a clinical testing laboratory with all mandatory accrediting bodies, and (2) continually demonstrates that its testing protocols and procedures achieve a high degree of analytical accuracy.

Laboratory Certification: CLIA # 11D2073885

Laboratory Director: John Hanson, PhD

1903181001 - TEST, UTI - Reported Apr 02, 2019

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2019, Coriell Life Sciences Inc.

Powered by:
CORIELL
LIFE SCIENCES